PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while TRVN stands at 124.69%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-83.05%
Negative gross profit growth while TRVN is at 90.22%. Joel Greenblatt would examine cost competitiveness or demand decline.
7.21%
EBIT growth above 1.5x TRVN's 2.65%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
7.21%
Operating income growth above 1.5x TRVN's 2.65%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
7.01%
Net income growth under 50% of TRVN's 53.49%. Michael Burry would suspect the firm is falling well behind a key competitor.
8.82%
EPS growth under 50% of TRVN's 65.85%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
8.82%
Diluted EPS growth under 50% of TRVN's 65.85%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.91%
Share reduction more than 1.5x TRVN's 36.13%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.91%
Diluted share reduction more than 1.5x TRVN's 36.13%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
1.55%
Positive OCF growth while TRVN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
1.40%
Positive FCF growth while TRVN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
91.07%
Positive long-term OCF/share growth while TRVN is negative. John Neff would see a structural advantage in sustained cash generation.
81.18%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
13.88%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
98.43%
Net income/share CAGR above 1.5x TRVN's 38.39% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
78.58%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
-7.39%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
109.82%
Positive growth while TRVN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
14.99%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-59.15%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
19.47%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-6.20%
We’re deleveraging while TRVN stands at 0.73%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.94%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.45%
SG&A growth well above TRVN's 31.50%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.